|
STONY BROOK, NY--(Marketwired - November 02, 2016) - Applied DNA Sciences, Inc. ("Applied DNA" or the "Company") (NASDAQ: APDN), a provider of DNA-based supply chain, anti-counterfeiting, authentication, genotyping and anti-theft technologies, today announced that it has entered into a securities purchase agreement with a single healthcare dedicated institutional investor to purchase $5 million of common stock and warrants at a combined price of $2.20 per share of common stock and warrant. In the private placement, Applied DNA has agreed to sell 2,272,727 shares of its common stock and warrants to purchase 2,272,727 shares of its common stock. The warrants will have the same terms as the Company's existing publicly traded warrants (NASDAQ: APDNW) with an exercise price of $3.50 per share and an expiration date of November 20, 2019. |